Around 10 million people globally live with the life-threatening Human T-cell leukemia virus type 1 (HTLV-1), a pervasive yet poorly understood pathogen for which there are currently no preventative treatments and no cure. However, a landmark study co-led by Australian researchers has unveiled a significant breakthrough, demonstrating that existing HIV drugs can effectively suppress the transmission of the HTLV-1 virus in specially developed mouse models. This pivotal research, published in the esteemed journal Cell, paves the way for the first potential treatments to prevent the spread of this long-neglected virus, which is particularly endemic among many First Nations communities around the world, including those in Central Australia. The collaborative effort, spearheaded by researchers from the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute), not only identifies a promising prophylactic strategy but also pinpoints a novel drug target. This secondary discovery holds the potential to lead to therapies that could selectively eliminate HTLV-1 positive cells in individuals with an established infection, thereby preventing disease progression and offering a pathway toward a functional cure. The HTLV-1 Enigma: A Global Health Challenge Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus, much like HIV, that primarily infects T-cells – a crucial type of white blood cell integral to the body’s immune system. Discovered in the early 1980s, HTLV-1 was the first human retrovirus identified and has since been recognized as the causative agent for several severe and often fatal diseases. While a large proportion of infected individuals remain asymptomatic carriers throughout their lives, an estimated 5-10% will, after a prolonged latency period that can span decades, develop serious complications. These include Adult T-cell Leukemia/Lymphoma (ATL), an aggressive and often deadly cancer of the T-cells, and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating neurodegenerative disorder characterized by progressive paralysis and sensory disturbances. Other associated conditions include HTLV-1 uveitis, infective dermatitis, and various inflammatory diseases. The virus is transmitted through several routes: from mother to child (primarily via breastfeeding), sexually, and through contaminated blood products or organ transplantation. Its prevalence is geographically concentrated, with significant endemic regions including southwestern Japan, parts of sub-Saharan Africa, the Caribbean basin, and notably, Central Australia, where some Indigenous communities bear one of the highest HTLV-1 infection rates globally. Despite its significant health burden and the severity of the diseases it causes, HTLV-1 has historically suffered from a profound lack of research funding, public awareness, and global health prioritization, earning it the designation of one of the "most neglected viruses in the world." This neglect has resulted in a critical dearth of diagnostic tools, effective treatments, and preventative strategies, leaving millions vulnerable. A Decade of Dedicated Research: The Breakthrough Study The journey to this groundbreaking discovery was a meticulous and decade-long research endeavor. Co-lead author and WEHI laboratory head Dr. Marcel Doerflinger emphasized the profound significance of these findings, stating, "Our study marks the first time any research group has been able to suppress this virus in a living organism." He underscored the urgency, explaining, "As HTLV-1 symptoms can take decades to appear, by the time a person knows they have the infection, the immune damage is already in full swing. Suppressing the virus at transmission would allow us to stop it before it has the chance to cause irreversible damage to immune function, leading to disease and a premature death." A cornerstone of this extensive research was the development of a world-first humanized mouse model for HTLV-1. This innovative model was crucial, as it allowed researchers to meticulously study how the virus behaves and establishes infection within a living organism possessing a human-like immune system, an unprecedented feat in HTLV-1 research. The mice were engrafted with human immune cells that are susceptible to HTLV-1 infections, enabling a physiologically relevant environment for viral propagation and disease manifestation. The team successfully infected these models with both international HTLV-1 strains and Australia’s unique, genetically novel HTLV-1c strain, observing that both strains equally induced severe pathologies such as leukemia and inflammatory lung disease in these human immune system mice, thereby validating the model’s utility for disease modeling. Repurposing Existing Therapies: A Swift Path to Prevention Following the establishment of these sophisticated models, the research team embarked on testing potential antiviral interventions. They administered tenofovir and dolutegravir to the infected mice – two potent antiviral therapies that are well-established and widely used to control HIV infection and prevent AIDS. The results were remarkably clear: both drugs demonstrated a powerful capacity to suppress HTLV-1, significantly reducing viral load and preventing transmission. The implications of this finding are immense, particularly because these drugs are already approved, widely available, and have a proven safety profile in millions of HIV patients worldwide. Dr. Doerflinger highlighted this advantage, stating, "What’s most exciting is that these antivirals are already in use for millions of HIV patients, meaning there’s a direct path for the clinical translation of our findings. We won’t have to start from scratch because we already know these drugs are safe and effective. And now we’ve shown that their use can very likely be extended to HTLV-1." This potential for drug repurposing dramatically accelerates the timeline for bringing a preventative treatment to those at risk of HTLV-1 infection, bypassing years of costly and complex drug development and safety trials typically required for novel compounds. The immediate goal is to establish these drugs as the first approved pre-exposure prophylaxis (PrEP) against HTLV-1 acquisition, offering a tangible preventative measure for vulnerable populations. Beyond Prevention: Targeting Established Infection and Disease Progression In an equally remarkable discovery, the research team ventured beyond prevention, exploring strategies to tackle established HTLV-1 infections. They found that human cells containing HTLV-1 could be selectively targeted and eliminated when mice were treated with HIV drugs in combination with another therapy. This additional therapy specifically inhibited a protein known as MCL-1 (Myeloid Cell Leukemia Sequence 1), which plays a critical role in promoting the survival of rogue cells, including those infected with HTLV-1. This dual-pronged approach suggests a potential curative strategy. By combining antivirals to suppress the virus with an MCL-1 inhibitor to selectively kill infected cells, researchers envision a pathway to clear the virus from the body, or at least significantly reduce the reservoir of infected cells, thereby preventing or reversing disease progression. The team is now actively leveraging precision RNA therapies to develop new ways to target MCL-1 and establish optimized combination treatments. These novel therapeutic strategies are being developed with a view towards future clinical testing, offering a promising avenue for those already living with HTLV-1 and its associated diseases. The Critical Role of Humanized Mouse Models The development of the sophisticated humanized mouse models, central to the success of this study, was a monumental undertaking spearheaded by first author Dr. James Cooney and Professor Marc Pellegrini, a study lead author, WEHI Honorary Fellow, and Executive Director at the Centenary Institute. Professor Pellegrini underscored the transformative impact of these models: "Our study provides critical insights that enable us to better understand the consequences of the distinct molecular make-up of the virus affecting our First Nations communities. This will further help us to investigate ways to create the tools needed to control the spread of this virus subtype." These models were not merely instrumental in identifying potential therapeutic targets; they also provided unprecedented opportunities to understand how different strains of the HTLV-1 virus might influence disease symptoms and outcomes. This is particularly vital for understanding the unique characteristics of HTLV-1c, the strain predominant in Australia. For decades, researchers have hypothesized that variations in viral subtypes could impact disease manifestation, but robust evidence has been scarce due to the limited research infrastructure for HTLV-1. The new models have finally provided the necessary platform to test and confirm such hypotheses, offering a granular understanding of the virus’s pathogenesis. Understanding HTLV-1 Strains: Insights from Australia’s Unique Subtype The human HTLV-1 samples crucial for developing these mouse models were obtained through the dedicated front-line clinical work of Associate Professor Lloyd Einsiedel, a Clinician Scientist at the Doherty Institute and an Infectious Diseases Physician. For over a decade, Associate Professor Einsiedel has provided essential clinical services to Central Australia, dedicating his career to raising the profile of HTLV-1 and understanding its impact on First Nations communities. Further enriching this understanding, Professor Damian Purcell, Head of Molecular Virology at the Doherty Institute and co-lead author of the study, meticulously isolated the virus from First Nations donors. His research confirmed significant genetic differences between the HTLV-1c strains prevalent in Central Australia and the HTLV-1a strains typically found internationally. The new findings from the humanized mouse models have unequivocally shown that both HTLV-1 strains are capable of causing disease, with HTLV-1c exhibiting more aggressive features in these models. Crucially, the identified drug therapies (tenofovir and dolutegravir) were found to be equally effective against both the HTLV-1a and the more aggressive HTLV-1c strains, a finding that holds immense promise for affected communities in Australia. Advocacy and Global Recognition: Elevating a Neglected Threat The scientific breakthroughs are also a testament to years of tireless advocacy. Professor Purcell and Associate Professor Einsiedel, working closely with the National Aboriginal Community Controlled Health Organization (NACCHO) HTLV-1 committee and the Australian Department of Health, championed the need for international recognition and guidance on HTLV-1. Their persistent efforts culminated in a major victory in 2021 when the World Health Organization (WHO) formally classified HTLV-1 as a Threatening Pathogen to Humans. This crucial WHO classification was a turning point, leading to the development of formal WHO policies aimed at reducing HTLV-1 transmission internationally. Concurrently, under the leadership of NACCHO, specific clinical management guidelines for HTLV-1c in Central Australia were developed, addressing the unique challenges faced by Indigenous communities. Despite these advancements, Professor Purcell highlighted the ongoing challenges: "Despite Australia’s high burden of HTLV-1, the virus and its associated diseases are still not notifiable in most states, and true infection rates in the nation remain unknown." This lack of consistent surveillance impedes effective public health responses and resource allocation. He passionately argued for equitable access to medical tools, stating, "People at risk from HTLV-1 deserve biomedical tools like those that provide game-changing therapeutic and prevention options for other blood-borne persistent viral infections, such as HIV." He concluded with a hopeful outlook: "There is a real opportunity to prevent the transmission of HTLV-1 and end the diseases caused by these infections. Our research findings are a major leap forward in this." Future Horizons: Clinical Translation and Public Health Impact The immediate next steps involve active discussions between the research team and the pharmaceutical companies behind the HIV antivirals used in this study. The goal is to explore the possibility of including HTLV-1 patients in ongoing or future clinical trials. If successful, this would fast-track the approval process, potentially making these drugs the first officially sanctioned pre-exposure prophylaxis (PrEP) against HTLV-1 acquisition. Such a development would be transformative, offering a concrete tool for prevention, particularly in high-prevalence areas. The broader implications of this research extend far beyond HTLV-1. The success in developing humanized mouse models and identifying drug repurposing opportunities sets a precedent for accelerating research into other neglected tropical diseases and viral infections. Furthermore, the findings underscore the critical importance of international collaboration and sustained advocacy in addressing global health inequities. For First Nations communities in Australia and other endemic regions globally, this research offers a beacon of hope for a future free from the devastating impact of HTLV-1 and its associated diseases. This pioneering research was made possible through the generous support of The Australian Centre for HIV and Hepatitis Virology Research, The Phyllis Connor Memorial Trust, Drakensberg Trust, and the National Health and Medical Research Council (NHMRC), highlighting the vital role of sustained funding in scientific discovery. Post navigation This vaccine uses dental floss instead of needles
